Carregant...
Widespread Changes in Positive Allosteric Modulation of the Muscarinic M(1) Receptor in Some Participants With Schizophrenia
BACKGROUND: Preclinical and some human data suggest allosteric modulation of the muscarinic M(1) receptor (CHRM1) is a promising approach for the treatment of schizophrenia. However, it is suggested there is a subgroup of participants with schizophrenia who have profound loss of cortical CHRM1 (MRDS...
Guardat en:
| Publicat a: | Int J Neuropsychopharmacol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6822142/ https://ncbi.nlm.nih.gov/pubmed/31428788 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ijnp/pyz045 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|